Sysmex Inostics
Chris Dougherty currently serves as the Supervisor of the Clinical Testing Laboratory at Sysmex Inostics, a position held since February 2022. Prior to this role, Chris was a Technical Specialist in HLA at the University of Maryland Medical Center from March 2017 to February 2022 and worked as an Immunogenetics Lab Tech II at Johns Hopkins Immunogenetics Lab from September 2013 to March 2017. Earlier experience includes working as a Lab Technician at Raptor Detection Technologies, LLC from February 2011 to June 2013, where the company specialized in detecting trace amounts of explosives using Molecularly Imprinted Polymers (MIPs). Additionally, Chris contributed as an Independent Research Student at UMD Cell Biology and Molecular Genetics in 2012 under the guidance of Dr. Steven Hutcheson. Chris holds a Master of Science in Biotechnology with a concentration in Biotechnology Enterprise from Johns Hopkins University (2014-2019) and a Bachelor of Science in Biology from the University of Maryland (2009-2012).
This person is not in any teams
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.